Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
A Phase II Trial of Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
Status: Enrolling
Updated:  5/9/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
A Phase II Trial of Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
Status: Enrolling
Updated: 5/9/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
The Jewels in Our Genes Study - an African American Family Study of Breast Cancer
Search for Novel Breast Cancer Susceptibility Genes in Pedigrees of African Ancestry
Status: Enrolling
Updated:  5/10/2016
University at Buffalo
mi
from
Buffalo, NY
The Jewels in Our Genes Study - an African American Family Study of Breast Cancer
Search for Novel Breast Cancer Susceptibility Genes in Pedigrees of African Ancestry
Status: Enrolling
Updated: 5/10/2016
University at Buffalo
mi
from
Buffalo, NY
Click here to add this to my saved trials
Rapid Radiation Therapy for Painful Osseous Metastatic Disease
Phase II Pilot Single Arm Prospective Clinical Trial of Rapid Institution of Helical TomoTherapy-based Radiation Therapy for Patients With Painful Osseous Metastatic Disease
Status: Enrolling
Updated:  5/10/2016
University of Virginia
mi
from
Charlottesville, VA
Rapid Radiation Therapy for Painful Osseous Metastatic Disease
Phase II Pilot Single Arm Prospective Clinical Trial of Rapid Institution of Helical TomoTherapy-based Radiation Therapy for Patients With Painful Osseous Metastatic Disease
Status: Enrolling
Updated: 5/10/2016
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Comparison of Dermal Autograft to AlloDerm in Breast Reconstruction
A Comparison of Dermal Autograft to Commercially Available Dermal Allograft in Breast Reconstruction
Status: Enrolling
Updated:  5/10/2016
University of Kentucky Chandler Medical Center
mi
from
Lexington, KY
A Comparison of Dermal Autograft to AlloDerm in Breast Reconstruction
A Comparison of Dermal Autograft to Commercially Available Dermal Allograft in Breast Reconstruction
Status: Enrolling
Updated: 5/10/2016
University of Kentucky Chandler Medical Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Examining the Relationships Between Sleep, Fatigue, and Pain in Aromatase Inhibitor-treated Patients
Prospective Pilot Study Evaluating the Inter-relationships Between Sleep Disturbance, Fatigue, Pain, and Daytime Activity in Breast Cancer Patients Starting Aromatase Inhibitor Therapy
Status: Enrolling
Updated:  5/10/2016
University of Michigan Health System
mi
from
Ann Arbor, MI
Examining the Relationships Between Sleep, Fatigue, and Pain in Aromatase Inhibitor-treated Patients
Prospective Pilot Study Evaluating the Inter-relationships Between Sleep Disturbance, Fatigue, Pain, and Daytime Activity in Breast Cancer Patients Starting Aromatase Inhibitor Therapy
Status: Enrolling
Updated: 5/10/2016
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer
Randomized-Controlled, Pilot Study of the Effects of a Brief, Scripted Sexual Health Intervention on Sexual Function for Women With Gynecologic Cancer
Status: Enrolling
Updated:  5/10/2016
University of Wisconsin-Madison
mi
from
Madison, WI
Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer
Randomized-Controlled, Pilot Study of the Effects of a Brief, Scripted Sexual Health Intervention on Sexual Function for Women With Gynecologic Cancer
Status: Enrolling
Updated: 5/10/2016
University of Wisconsin-Madison
mi
from
Madison, WI
Click here to add this to my saved trials
Study to Education Childhood Cancer Survivors About Survivorship Care
Childhood Cancer Survivor Program to Empower Action in Care
Status: Enrolling
Updated:  5/10/2016
University of Illinois at Chicago
mi
from
Chicago, IL
Study to Education Childhood Cancer Survivors About Survivorship Care
Childhood Cancer Survivor Program to Empower Action in Care
Status: Enrolling
Updated: 5/10/2016
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes
Status: Enrolling
Updated:  5/11/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes
Status: Enrolling
Updated: 5/11/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
A Phase I Trial of Escalating Doses of the Anti-IGF-1R Monoclonal Antibody IMC-A12 and Standard Dose Sorafenib for Treatment of Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  5/11/2016
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
A Phase I Trial of Escalating Doses of the Anti-IGF-1R Monoclonal Antibody IMC-A12 and Standard Dose Sorafenib for Treatment of Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 5/11/2016
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
A Phase I Trial of Escalating Doses of the Anti-IGF-1R Monoclonal Antibody IMC-A12 and Standard Dose Sorafenib for Treatment of Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  5/11/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
A Phase I Trial of Escalating Doses of the Anti-IGF-1R Monoclonal Antibody IMC-A12 and Standard Dose Sorafenib for Treatment of Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 5/11/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
A Phase I Trial of Escalating Doses of the Anti-IGF-1R Monoclonal Antibody IMC-A12 and Standard Dose Sorafenib for Treatment of Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  5/11/2016
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
A Phase I Trial of Escalating Doses of the Anti-IGF-1R Monoclonal Antibody IMC-A12 and Standard Dose Sorafenib for Treatment of Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 5/11/2016
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
A Phase I Trial of Escalating Doses of the Anti-IGF-1R Monoclonal Antibody IMC-A12 and Standard Dose Sorafenib for Treatment of Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  5/11/2016
Penn State Hershey Cancer Institute-Clinical Trials Office
mi
from
Hershey, PA
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
A Phase I Trial of Escalating Doses of the Anti-IGF-1R Monoclonal Antibody IMC-A12 and Standard Dose Sorafenib for Treatment of Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 5/11/2016
Penn State Hershey Cancer Institute-Clinical Trials Office
mi
from
Hershey, PA
Click here to add this to my saved trials
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
A Phase I Trial of Escalating Doses of the Anti-IGF-1R Monoclonal Antibody IMC-A12 and Standard Dose Sorafenib for Treatment of Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  5/11/2016
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
A Phase I Trial of Escalating Doses of the Anti-IGF-1R Monoclonal Antibody IMC-A12 and Standard Dose Sorafenib for Treatment of Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 5/11/2016
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
A Phase I Trial of Escalating Doses of the Anti-IGF-1R Monoclonal Antibody IMC-A12 and Standard Dose Sorafenib for Treatment of Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  5/11/2016
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
A Phase I Trial of Escalating Doses of the Anti-IGF-1R Monoclonal Antibody IMC-A12 and Standard Dose Sorafenib for Treatment of Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 5/11/2016
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients
Self-Administered Guided Imagery in the Perioperative Period to Reduce Postoperative Distress in Gynecologic Oncology Patients: A Randomized Control Trial
Status: Enrolling
Updated:  5/11/2016
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients
Self-Administered Guided Imagery in the Perioperative Period to Reduce Postoperative Distress in Gynecologic Oncology Patients: A Randomized Control Trial
Status: Enrolling
Updated: 5/11/2016
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors
A Phase I Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/12/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors
A Phase I Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/12/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors
A Phase I Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/12/2016
Brigham and Women's Hosp
mi
from
Boston, MA
A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors
A Phase I Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/12/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Effects of Exemestane on Bone Strength
Effects of Exemestane on Bone Strength in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated:  5/12/2016
University of California-Davis
mi
from
Sacramento, CA
Effects of Exemestane on Bone Strength
Effects of Exemestane on Bone Strength in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated: 5/12/2016
University of California-Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials
Effects of Exemestane on Bone Strength
Effects of Exemestane on Bone Strength in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated:  5/12/2016
The Mayo Clinic
mi
from
Rochester, MN
Effects of Exemestane on Bone Strength
Effects of Exemestane on Bone Strength in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated: 5/12/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Effects of Exemestane on Bone Strength
Effects of Exemestane on Bone Strength in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated:  5/12/2016
University Health Network, TGH
mi
from
Toronto,
Effects of Exemestane on Bone Strength
Effects of Exemestane on Bone Strength in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated: 5/12/2016
University Health Network, TGH
mi
from
Toronto,
Click here to add this to my saved trials
Prostate Cancer Utilities and Cost-Effectiveness Analysis
Prostate Cancer Utilities and Cost-Effectiveness Analysis
Status: Enrolling
Updated:  5/17/2016
University of Chicago
mi
from
Chicago, IL
Prostate Cancer Utilities and Cost-Effectiveness Analysis
Prostate Cancer Utilities and Cost-Effectiveness Analysis
Status: Enrolling
Updated: 5/17/2016
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
Status: Enrolling
Updated:  5/17/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
Status: Enrolling
Updated: 5/17/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated:  5/17/2016
Adventist Midwest Health
mi
from
Hinsdale, IL
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated: 5/17/2016
Adventist Midwest Health
mi
from
Hinsdale, IL
Click here to add this to my saved trials
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated:  5/17/2016
Aurora St. Luke's Medical Center
mi
from
Milwaukee, WI
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated: 5/17/2016
Aurora St. Luke's Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated:  5/17/2016
Carolinas Medical Center
mi
from
Charlotte, NC
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated: 5/17/2016
Carolinas Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated:  5/17/2016
Fletcher Allen Health Care
mi
from
Burlington, VT
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated: 5/17/2016
Fletcher Allen Health Care
mi
from
Burlington, VT
Click here to add this to my saved trials
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated:  5/17/2016
Lenox Hill Hospital
mi
from
New York, NY
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated: 5/17/2016
Lenox Hill Hospital
mi
from
New York, NY
Click here to add this to my saved trials
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated:  5/17/2016
Memorial Healthcare
mi
from
Pembroke Pines, FL
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated: 5/17/2016
Memorial Healthcare
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated:  5/17/2016
Methodist Hospital Dallas
mi
from
Dallas, TX
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated: 5/17/2016
Methodist Hospital Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated:  5/17/2016
Montefiore Medical Center
mi
from
Bronx, NY
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated: 5/17/2016
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated:  5/17/2016
Orlando Health
mi
from
Orlando, FL
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated: 5/17/2016
Orlando Health
mi
from
Orlando, FL
Click here to add this to my saved trials
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated:  5/17/2016
Roswell Park Cancer Center
mi
from
Buffalo, NY
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated: 5/17/2016
Roswell Park Cancer Center
mi
from
Buffalo, NY
Click here to add this to my saved trials
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated:  5/17/2016
Spartanburg Regional Healthcare / Gibbs Cancer Center
mi
from
Spartanburg, SC
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated: 5/17/2016
Spartanburg Regional Healthcare / Gibbs Cancer Center
mi
from
Spartanburg, SC
Click here to add this to my saved trials
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated:  5/17/2016
St. Mark's Hospital
mi
from
Salt Lake City, UT
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated: 5/17/2016
St. Mark's Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated:  5/17/2016
University of Illinois at Chicago
mi
from
Chicago, IL
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated: 5/17/2016
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated:  5/17/2016
University of Maryland Medical Center
mi
from
Baltimore, MD
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated: 5/17/2016
University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated:  5/17/2016
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated: 5/17/2016
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated:  5/17/2016
West Virginia University Healthcare
mi
from
Morgantown, WV
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated: 5/17/2016
West Virginia University Healthcare
mi
from
Morgantown, WV
Click here to add this to my saved trials
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated:  5/17/2016
City of Hope
mi
from
Duarte, CA
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated: 5/17/2016
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated:  5/17/2016
Ochsner Clinic Foundation
mi
from
New Orleans, LA
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated: 5/17/2016
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Click here to add this to my saved trials
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated:  5/17/2016
Gosford Hospital
mi
from
Gosford,
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study
Status: Enrolling
Updated: 5/17/2016
Gosford Hospital
mi
from
Gosford,
Click here to add this to my saved trials
Biomarkers in Patients With Advanced Rhabdomyosarcoma
Developmental Pathway Drug-Targets in Advanced Rhabdomyosarcomas
Status: Enrolling
Updated:  5/17/2016
Children's Oncology Group
mi
from
Philadelphia, PA
Biomarkers in Patients With Advanced Rhabdomyosarcoma
Developmental Pathway Drug-Targets in Advanced Rhabdomyosarcomas
Status: Enrolling
Updated: 5/17/2016
Children's Oncology Group
mi
from
Philadelphia, PA
Click here to add this to my saved trials
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Administration of LMP-Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma (ALCI)
Status: Enrolling
Updated:  5/18/2016
Texas Children's Hospital
mi
from
Houston, TX
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Administration of LMP-Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma (ALCI)
Status: Enrolling
Updated: 5/18/2016
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Administration of LMP-Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma (ALCI)
Status: Enrolling
Updated:  5/18/2016
Methodist Hospital
mi
from
Houston, TX
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Administration of LMP-Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma (ALCI)
Status: Enrolling
Updated: 5/18/2016
Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
Status: Enrolling
Updated:  5/18/2016
Children's Hospital of Alabama
mi
from
Birmingham, AL
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
Status: Enrolling
Updated: 5/18/2016
Children's Hospital of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
Status: Enrolling
Updated:  5/18/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
Status: Enrolling
Updated: 5/18/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
Status: Enrolling
Updated:  5/18/2016
University of South Alabama
mi
from
Mobile, AL
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
Status: Enrolling
Updated: 5/18/2016
University of South Alabama
mi
from
Mobile, AL
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
Status: Enrolling
Updated:  5/18/2016
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
Status: Enrolling
Updated: 5/18/2016
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
Status: Enrolling
Updated:  5/18/2016
University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
Status: Enrolling
Updated: 5/18/2016
University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
Status: Enrolling
Updated:  5/18/2016
Southern California Permanente Medical Group
mi
from
Downey, CA
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
Status: Enrolling
Updated: 5/18/2016
Southern California Permanente Medical Group
mi
from
Downey, CA
Click here to add this to my saved trials